PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells. PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites...
Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.065 | -4.14012738854 | 1.57 | 1.61 | 1.42 | 206331 | 1.51586837 | CS |
4 | -0.105 | -6.52173913043 | 1.61 | 1.69 | 1.42 | 224779 | 1.58096353 | CS |
12 | -0.005 | -0.331125827815 | 1.51 | 1.82 | 1.42 | 203333 | 1.59332482 | CS |
26 | -0.105 | -6.52173913043 | 1.61 | 1.82 | 1.4 | 222870 | 1.57777045 | CS |
52 | -0.745 | -33.1111111111 | 2.25 | 3.47 | 1.4 | 368176 | 1.78881285 | CS |
156 | -21.465 | -93.4479756204 | 22.97 | 24.265 | 1.175 | 622722 | 9.04934519 | CS |
260 | -33.545 | -95.7061340942 | 35.05 | 63.22 | 1.175 | 525859 | 12.75620568 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales